Sign In
Buy ACRS
$4.42
-0.210 (-4.54%)
At Close: Jun 03, 2026
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Lags Revenue Estimates
09:57am, Tuesday, 02'nd Nov 2021
Aclaris (ACRS) delivered earnings and revenue surprises of -29.63% and -9.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
04:01pm, Friday, 27'th Aug 2021
WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
07:00am, Thursday, 05'th Aug 2021
WAYNE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
04:43pm, Friday, 30'th Jul 2021
Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More
09:11am, Tuesday, 15'th Jun 2021
Tuesday's futures were fairly positive after a somewhat mixed start to the week.
Aclaris Announces Pricing of Public Offering of Common Stock
07:55pm, Wednesday, 09'th Jun 2021
WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory d
Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
12:01pm, Wednesday, 09'th Jun 2021
Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.
Aclaris Announces Proposed Public Offering of Common Stock
04:15pm, Tuesday, 08'th Jun 2021
WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
RMED, HOOK, JZXN, ACRS, OPRA, CVAC Stock Prices Fall Intraday
02:41pm, Tuesday, 08'th Jun 2021
The stock prices of RMED, HOOK, JZXN, ACRS, OPRA, and CVAC have fallen noticeably today. These are the details.
Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure
07:46am, Tuesday, 08'th Jun 2021
Aclaris Therapeutics Inc (NASDAQ: ACRS) has announced preliminary topline results from its Phase 2a trial evaluating ATI-1777 for moderate to severe atopic dermatitis (AD). The primary efficacy end
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
09:46am, Friday, 07'th May 2021
Aclaris (ACRS) delivered earnings and revenue surprises of -111.11% and 20.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update
07:00am, Friday, 07'th May 2021
WAYNE, Pa., May 07, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory d
Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon
04:00pm, Tuesday, 02'nd Mar 2021
Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
11:18am, Wednesday, 20'th Jan 2021
Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.
Aclaris Announces Pricing of Public Offering of Common Stock
08:45am, Wednesday, 20'th Jan 2021
WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory d
